Thromboembolism in adults with acute lymphoblastic leukemia (ALL) during induction with L-asparaginase (ASP)-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin (AT) in pathogenesis and prophylaxis.

被引：0
|
作者：
Elliott, MA [1 ]
Wolf, RC [1 ]
Hook, CC [1 ]
Pruthi, RK [1 ]
Heit, JA [1 ]
Letendre, LL [1 ]
Tefferi, A [1 ]
Kaufmann, SH [1 ]
Mesa, RA [1 ]
Litzow, MR [1 ]
机构：
[1] Mayo Clin & Mayo Fdn, Dept Internal Med, Div Hematol, Rochester, MN 55905 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3269
引用
收藏
页码：878A / 878A
页数：1
相关论文
共 6 条
  • [1] Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: Incidence, risk factors, and possible role of antithrombin
    Elliott, MA
    Wolf, RC
    Hook, CC
    Pruthi, RK
    Heit, JA
    Letendre, LL
    Tefferi, A
    Kaufmann, SH
    Mesa, RA
    Litzow, MR
    LEUKEMIA & LYMPHOMA, 2004, 45 (08) : 1545 - 1549
  • [2] Safety and Efficacy of Enoxaparin Prophylaxis in Adults Receiving Peg-Asparaginase Containing Induction Regimens for Acute Lymphoblastic Leukemia (ALL)
    Umakanthan, Jayadev Manikkam
    Maness, Lori J.
    Luo, Jiangtao
    Kallam, Avyakta
    Armitage, James O.
    Bierman, Philip
    Vose, Julie M.
    Bociek, R. Gregory
    Lunning, Matthew
    Gundabolu, Krishna
    Bhatt, Vijaya R.
    BLOOD, 2016, 128 (22)
  • [3] Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens
    Kashanian, Sarah M.
    Holtzman, Noa G.
    Patzke, Ciera L.
    Cornu, Jonathan
    Duffy, Alison
    Koka, Madhurima
    Niyongere, Sandrine
    Duong, Vu H.
    Baer, Maria R.
    Apata, Jummai
    Kamangar, Farin
    Emadi, Ashkan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (06) : 817 - 826
  • [4] Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens
    Sarah M. Kashanian
    Noa G. Holtzman
    Ciera L. Patzke
    Jonathan Cornu
    Alison Duffy
    Madhurima Koka
    Sandrine Niyongere
    Vu H. Duong
    Maria R. Baer
    Jummai Apata
    Farin Kamangar
    Ashkan Emadi
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 817 - 826
  • [5] Shift to Anti-Fibrinolysis on the Administration of L-Asparaginase (L-Asp) during Induction Therapy for Pediatric Acute Lymphoblastic Leukemia (ALL)
    Ishihara, Takashi
    Nogami, Keiji
    Matsumoto, Tomoko
    Takeshita, Yasufumi
    Nomura, Akitaka
    Ochi, Satoshi
    Ishida, Toshiaki
    Kosaka, Yoshiyuki
    Sawada, Akihisa
    Inoue, Masami
    Shima, Midori
    BLOOD, 2016, 128 (22)
  • [6] Evolution of antithrombin (AT) and fibrinogen (Fg) levels during induction chemotherapy with L-asparaginase (Asp) in adult patients with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). Clinical outcomes and use of coagulation supportive treatments: The CAPELAL study
    Hunault-Berger, M
    Gruel, Y
    Harousseau, JL
    Delain, M
    Maakaroun, A
    Bulabois, CE
    Witz, F
    Bernard, M
    Lafon, I
    Cornillon, J
    Ladouzi, A
    Tizon, A
    Padrazzi, B
    Tellier, Z
    Ifrah, N
    BLOOD, 2004, 104 (11) : 204B - 204B
1